We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PERSONALISED THERAPY FOR MELANOMA.
- Authors
Broziĉ, Jasmina Mariĉ; Ðakoviĉ, Nikola
- Abstract
In the therapy of metastatic melanoma, prior to 2011 the only approved treatment option were dacarbazine and interleukin-2, with a small percentage of patients with good response; no study involving these agents had shown an improvement in overall survival. Researches in the last decades have contributed to a better understanding of melanoma. The discovery that BRAF is a driver oncogene in cancer and complementary improvements in our understanding of the immune system have resulted in new targeted and immune-therapies for metastatic melanoma. Targeted therapies can achieve impressive clinical results in large number of patients, but the resistance to the therapy is often present. Immune therapy can achieve long-term remission and cures, yet in a smaller proportion of patients, and we still have no biomarkers to predict which patients will respond. Nevertheless, melanoma has led the evolution of cancer treatment from relatively non-specific cytotoxic agents to highly selective therapies, which offer an improvement in the outcome for melanoma patients. Still, many open questions remain: how to avoid resistance to therapy; how to find biomakers to predict answer to therapy; and how to find the optimal treatment options for patients who relapse or do not respond.
- Subjects
MELANOMA treatment; DACARBAZINE; INTERLEUKIN-2; CANCER treatment; BRAF genes; ONCOGENES; IMMUNOTHERAPY; THERAPEUTICS
- Publication
Rad Hrvatske Akademije Znanosti i Umjetnosti. Medicinske Znanosti, 2014, Vol 520, Issue 40, p51
- ISSN
1330-5301
- Publication type
Article